 UBBFriend: Email This Page to Someone! |
 Investorville
 V
 Variagenics (VGNX)
|
| next newest topic | next oldest topic |
| Author | Topic: Variagenics (VGNX) |
|
Earnings Administrator |
posted 08-29-2000 06:23 PM
 
Company Name (Ticker): reported, expected, same q last year Variagenics (VGNX): -$5.73, n/a, -$6.34 |
|
InvestorGuide Daily Administrator |
posted 07-21-2000 06:03 PM
Bitoech company Variagenics (VGNX) priced at $14, opened at $22.75, closed at $23.44, and raised $70 million. |
|
Mayor of Investorville Administrator |
posted 04-03-2000 12:01 PM
Variagenics uses pharmacogenomics, which studies links between genetic variability and response to drugs, to develop new drugs and diagnostic products. Products being developed include the Variagenic Impact Program, which analyzes SNP data to identify drug targets, and the NuCleave DNA analysis platform, which performs assays on DNA samples to examine patients' responses to drugs. Initially focused on cancer, the company is now also targeting cardiovascular, neurological, and inflammatory diseases. The company plans to go public soon and hopes to raise $100 million (source: SEC filing). |
All times are EST (US) | next newest topic | next oldest topic |
  |
|
Powered by: Ultimate Bulletin Board, Version 5.43
© Infopop Corporation (formerly Madrona Park, Inc.), 1998 - 2000.
Press ctrl-D to bookmark this page for future reference.
By using this site you agree to our Terms of Use.
Copyright 2001 InvestorGuide.com Inc.